ReShape Lifesciences Inc (RSLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has a cash flow conversion efficiency ratio of -0.771x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.49 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ReShape Lifesciences Inc to measure how much of total assets are equity-financed.
ReShape Lifesciences Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how ReShape Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RSLS operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
ReShape Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ReShape Lifesciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cinevista Limited
NSE:CINEVISTA
|
0.054x |
|
Micronet Ltd
TA:MCRNT
|
-0.126x |
|
Seacera Group Bhd
KLSE:7073
|
-0.001x |
|
Reach Resources Ltd
AU:RR1
|
-0.032x |
|
WALKER RIVER RES CORP
F:1WV0
|
-0.019x |
|
Domino’s Pizza Group PLC
LSE:DOM
|
-0.351x |
|
Hengli Industrial Development Group Co Ltd
SHE:000622
|
-0.027x |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
-1.314x |
Annual Cash Flow Conversion Efficiency for ReShape Lifesciences Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of ReShape Lifesciences Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of ReShape Lifesciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1692.69% |
| 2021-12-31 | $46.07 Million | $-15.38 Million | -0.334x | +43.45% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.18% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.15% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more